HOME >> BIOLOGY >> NEWS
ChemGenex uses genomics approach to develop new anticancer drug, predict possible side effects

Gene expression changes in response to drugs in cell culture and living systems provide unique insights for their development and use

MENLO PARK, CA (October 30, 2001): Most genomics research is currently aimed at identifying and validating new gene targets for use in early stage drug discovery. However, genomics can also play a key role now in preclinical and clinical drug development, including predicting potential drug toxicities and helping developers design clinical trials, say scientists from ChemGenex Therapeutics. They discussed data today illustrating the use of chemical genomics approaches in evaluating the potential of their investigational drug called Ceflatonin against leukemias and human solid tumors. The researchers presented their findings at the American Association of Cancer Research National Cancer Institute European Organization for Research and Treatment of Cancer conference on Molecular Targets and Cancer Therapeutics taking place from October 29 to November 3 in Orlando, Florida.

Understanding how genes perform in response to chemicals in cell cultures, as well as in diseased and normal tissues in living systems can help researchers identify and evaluate potential new drugs more efficiently than ever before, said Dennis Brown, Ph.D., chairman, chief executive officer and founder of ChemGenex Therapeutics, Inc.

Such knowledge can help spotlight possible drug toxicities, as well as identify which patients may best benefit from treatment with a specific drug, he continued. In addition, chemical genomics can aid in the design of efficient clinical trials by helping trial designers predict the most effective doses and dose scheduling, as well as provide key insights into drug bioavailability, distribution and metabolism. Using genomics in this way to help patients receive most effectively those medicines that will be most useful to them is a major goal of the genomics revolution.

Based on its chem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
30-Oct-2001


Page: 1 2 3

Related biology news :

1. International symposium on nutritional genomics
2. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
3. Full promise of genomics in disease research yet to be realized
4. Pharmacogenomics could replace trial-and-error with science from the human genome
5. Dartmouth Medical School awarded $9 million grant for genomics research
6. Functional genomics enables easy target identification and drives drug discovery
7. Library on a Slide: Whole genome microarrays for comparative genomics
8. New genomics tool boosts diabetes research
9. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology
10. Emerging frontiers genomics grant for blue-green bacteria
11. What can the genomics revolution teach us about global change?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... Reno, NV (PRWEB) , ... July 20, 2017 ... ... a real solution to make clinical trial sites and study participants truly unified. ... manage regulatory compliant (FDA 21 CFR Part 11) research studies entirely on mobile ...
(Date:7/18/2017)... ... July 18, 2017 , ... Blood centers traditionally see ... the region. Nationally, summer is a struggle for community blood centers as high schools ... San Antonio Chamber of Commerce is teaming up with the South Texas ...
(Date:7/17/2017)... (PRWEB) , ... July 17, ... ... of technology-enabled clinical trial solutions, today announced safety software company AB Cube ... the eHealth Solutions business segment to advance technology innovation across life sciences ...
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
Breaking Biology Technology:
Cached News: